David Scheer

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

Adela, Inc. is a company that is developing technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). The company is based in Branford, CT. The company's genome-wide methylome enrichment platform captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. Adela's approach to MRD testing is tissue agnostic, eliminating the burden of acquiring a tumor sample. The CEO of the company is Scott Bratman.

BiologicsMD, Inc. operates as early stage therapeutic development company. It focuses on developing highly-targeted or smart therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders. The company is headquartered in Fayetteville, AR.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

BiologicsMD, Inc. operates as early stage therapeutic development company. It focuses on developing highly-targeted or smart therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders. The company is headquartered in Fayetteville, AR.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.